Shares in Vertex Pharmaceuticals plunged 12% in Wednesday’s extended market session after the pharma company announced the decision to stop the development of …
Vertex (VRTX) is Cowen analyst’s top large-cap pick for the second year in a row. That’s how Phil Nadeau put it while increasing …
Biopharmaceutical Vertex’ (VRTX) is working on a trial called Phase III VX-659 and Cowen analyst Phil Nadeau calls some recently released data “Good …
By Genia Turanova There’s nothing like cash to show how successful a company has been. When a fledgling enterprise first turns cash-flow positive …
Maxim’s Jason McCarthy believes Vertex could “unlock” over 90% of the cystic fibrosis market as time passes.
2014 has been an eventful year on Wall Street. Now that the year is coming to an end, what stocks should investors be …
In a research report issued today, Vertex Pharmaceuticals (VRTX) was downgraded by analyst Andrew Fein at H.C.
In a research note released this morning, H.C.
In a research note released this morning, Janney Montgomery Scott reiterated coverage on Vertex Pharmaceuticals (VRTX) with an Outperform rating and $90 fair value estimate. A data …
